Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Dicerna Pharmaceutic (DRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 853,367
  • Shares Outstanding, K 68,324
  • Annual Sales, $ 6,180 K
  • Annual Income, $ -88,850 K
  • 60-Month Beta 2.30
  • Price/Sales 130.87
  • Price/Cash Flow N/A
  • Price/Book 4.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.32
  • Number of Estimates 6
  • High Estimate -0.12
  • Low Estimate -0.58
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.70 +16.73%
on 05/13/19
13.80 -9.49%
on 04/26/19
-1.04 (-7.69%)
since 04/24/19
3-Month
10.38 +20.33%
on 02/25/19
15.33 -18.53%
on 04/03/19
+1.98 (+18.84%)
since 02/22/19
52-Week
9.31 +34.16%
on 12/24/18
17.98 -30.53%
on 09/14/18
-1.30 (-9.43%)
since 05/24/18

Most Recent Stories

More News
Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced...

DRNA : 12.49 (+5.58%)
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -72.73% and -70.67%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

DRNA : 12.49 (+5.58%)
Dicerna(TM) Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update

---- Dosed First Healthy Volunteer in Phase 1 Clinical Trial of DCR-HBVS for Treatment of Chronic Hepatitis B Virus (HBV) Infection -

DRNA : 12.49 (+5.58%)
Dicerna(TM) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna(TM) Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the...

DRNA : 12.49 (+5.58%)
Dicerna(TM) to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019

Dicerna(TM) Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced...

DRNA : 12.49 (+5.58%)
Dicerna(TM) Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX(TM)2 Pivotal Trial

Dicerna(TM) Pharmaceuticals, Inc. (Nasdaq:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced...

DRNA : 12.49 (+5.58%)
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

ABUS : 1.91 (-4.50%)
DRNA : 12.49 (+5.58%)
ARWR : 24.04 (+9.42%)
ALNY : 68.93 (+1.50%)
REGN : 312.56 (-0.86%)
MRNA : 21.83 (+2.10%)
Dicerna(TM) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna(TM) Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the...

DRNA : 12.49 (+5.58%)
Dicerna(TM) to Present at the H.C. Wainwright Global Life Sciences Conference

Dicerna(TM) Pharmaceuticals, Inc.(Nasdaq:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced...

DRNA : 12.49 (+5.58%)
Dicerna(TM) Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

----Company Announces Initiation of Participant Screening for PHYOX2 Pivotal Trial in PH1 and PH2--

DRNA : 12.49 (+5.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRNA with:

Business Summary

Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 13.06
1st Resistance Point 12.77
Last Price 12.49
1st Support Level 12.10
2nd Support Level 11.72

See More

52-Week High 17.98
Fibonacci 61.8% 14.67
Fibonacci 50% 13.65
Fibonacci 38.2% 12.62
Last Price 12.49
52-Week Low 9.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar